



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

15 September 2016
EMA/565316/2016
Inspections, Human Medicines Pharmacovigilance and Committees Division

Agenda – 9th industry stakeholder platform – operation of EU pharmacovigilance

21 September 2016, 14:00-18:00, Meeting room 3E

Item	Preliminary draft agenda	Time
1.	Welcome and matters arising <ul style="list-style-type: none">– <i>Peter Arlett, Head of Pharmacovigilance and Epidemiology, EMA</i>– <i>June Raine, PRAC Chair, MHRA</i><ul style="list-style-type: none">○ <i>Including</i><ul style="list-style-type: none">– <i>Medical Literature Monitoring workshop feedback</i>– <i>ISO IDMP workshop feedback</i>– <i>European Commission report on 3 years Pharmacovigilance legislation</i>	14:00-14:30
2.	GVP VI ADR Reporting <ul style="list-style-type: none">• Initial perspective from industry<ul style="list-style-type: none">– <i>Industry representatives</i>• Discussion<ul style="list-style-type: none">– <i>Anja van Haren, MEB TC</i>– <i>Gilles Touraille, EMA</i>	14:30-15:00
3.	GVP IX on signal management <ul style="list-style-type: none">• Initial perspective from industry<ul style="list-style-type: none">– <i>Industry representatives</i>	15:00-15:30



Item	Preliminary draft agenda	Time
	<ul style="list-style-type: none"> Discussion <ul style="list-style-type: none"> <i>Sabine Straus, MEB</i> <i>Julie Durand, EMA</i> 	
4.	GVP PII Biologics <ul style="list-style-type: none"> Reflections from industry <ul style="list-style-type: none"> <i>Industry representatives</i> Discussion <ul style="list-style-type: none"> <i>Sabine Straus, MEB, Phil Bryan, MHRA</i> <i>Xavier Kurz, EMA</i> <i>All</i> 	15:30-16:10
	Coffee break	16:10-16:40
5.	Public hearings <ul style="list-style-type: none"> Presentation on public hearings dry-run and next steps <ul style="list-style-type: none"> <i>June Raine, PRAC Chair</i> <i>Nathalie Bere, EMA</i> Discussion <ul style="list-style-type: none"> <i>All</i> 	16:40-17:10
6.	Pharmacovigilance Impact <ul style="list-style-type: none"> Update and collaboration with industry <ul style="list-style-type: none"> <i>Thomas Goedecke, EMA</i> Discussion <ul style="list-style-type: none"> <i>All</i> 	17:10-17:40
9.	Conclusion and next steps	17:40-18:00
10.	Close of meeting	18:00

Participants List

Chair: Peter Arlett, Head of Pharmacovigilance & Epidemiology Department, EMA

- **PRAC**

- June Raine, PRAC **Chair**
- Almath Spooner, PRAC vice-Chair
- Margarida Guimarães, INFARMED
- Sabine Straus, MEB

- **CMDh**

- Peter Bachmann, CMDh **Chair**
- Kora Doorduyn - van der Stoep, MEB
- Virginie Bacquet, ANSM

- **EudraVigilance Expert Working Group**

- Anja van Haren, MEB **TC**

- **European Commission**

- Helen Lee

- **Medicines & Healthcare products Regulatory Agency**

- Phil Bryan

- **European Medicines Agency**

- Xavier Kurz, Head of Surveillance and Epidemiology, Pharmacovigilance & Epidemiology Department
- Georgy Genov, Head of Signal and Incident Management, Pharmacovigilance & Epidemiology Department
- Agnieszka Szmigiel, Signal and Incident Management, Pharmacovigilance & Epidemiology Department
- Marie-Helene Pinheiro, Industry Stakeholders Liaison, Corporate Stakeholders Department
- Jordi Llinares Garcia, Head of Scientific and Regulatory Management

- Maria Boulos, Human Medicines Research and Development Support Division, Regulatory Affairs
- Tom Paternoster-Howe, Data Standardisation and Analytics
- Sabine Brosch, Business Lead EudraVigilance and International Standardisation in Pharmacovigilance, Pharmacovigilance and Epidemiology Department
- Ioana Ratescu, Legal Administrator, Legal Department
- Gilles Touraille, Scientific Administrator, Signal and Incident Management, Pharmacovigilance & Epidemiology Department
- Julie Durand, Scientific Administrator, Signal and Incident Management, Pharmacovigilance & Epidemiology Department
- Nathalie Bere, Patients Liaison officer, Public Engagement Department
- Thomas Goedecke, Principal Scientific Administrator, Surveillance and Epidemiology, Pharmacovigilance & Epidemiology Department

Industry Stakeholder Organisations

• AESGP

- Yasmine Boulkroun, Head of Corporate Vigilances Division, Pierre Fabre
- Elmar Kroth, Director, German Medicines Manufacturers Association (BAH)
- Miranda Moussa, Manager for Safety Issues and Medical Devices, AESGP
- Lucy Pavesi, EU QPPV, Procter & Gamble
- Maria Spyt, EU QPPV, Johnson & Johnson

• EBE

- Zoe Conway, Deputy QPPV, Roche Products Limited
- Katrina Skeer, Director EMEA Regulatory Compliance & Business Support, Janssen-Cilag
- Catherine Akers, Regulatory Affairs Senior Manager, Amgen
- Veronique Debaut, Regulatory Affairs Manager, EBE

• EFPIA

- Vicki Edwards, Abbvie
- Guy Demol, MSD
- David Lewis, Novartis
- Sue Rees, Amgen

- Yogen Logesvaran, Jansen/J&J
- Sarah Montagne, Bayer
- Pari Nasser-Sina, GSK
- Jean Kilgour-Christie, Takeda

- **EUCOPE**

- Stefan Kaehler, Senior Director, Global Risk Management Standards & Special Advisor to the EEA QPPV, Global Drug Safety & Risk Management, Celgene Europe Ltd
- Alexandra Thrower, Global Director, Legal, Regulatory and Quality, Atlantis Healthcare
- John Poustie, Medical Director for Pharmacovigilance, Norgine
- Boris Thurisch, Head of Pharmacovigilance, BPI
- Philippe Bertrand, Head of Pharmacovigilance-Patient Safety & Drug Surveillance, EU QPPV, Onxeo
- Maren von Fritschen, Regulatory Director, EUCOPE
- Barbara Morollo, Senior Director, Pharmacovigilance, Bluebird Bio

- **EuropaBIO**

- Christiane Abouzeid, Head of Regulatory Affairs, BioIndustry Association (BIA)
- Margaret Walters, Deputy EU Qualified Person for Pharmacovigilance, MSD
- Esteban Herrero-Martinez, Director, Regulatory Policy & Intelligence, Abbvie
- Merete Schmiegelow, Senior Director, Regulatory Policy, Novo Nordisk
- Johan Hellmér, Global Drug Safety, Head EMEA, Shire

- **Europharm SMC**

- Margarida Estudante, Tecnifar
- Telma Costa, Tecnifar

- **Medicines for Europe**

- John Barber, BGMA
- Michael Forstner, Acino Pharma
- Tanja Peters, Boehringer Ingelheim
- Uwe Gudat, Merck
- Katarina Nedog, Medicines for Europe

- **Vaccines Europe**

- Françoise Dumas Sillan, QPPV Coordination Worldwide Safety and Regulatory, Pfizer
- Marc Ceuppens, Therapeutic Area Safety Head, Infectious Diseases and Vaccines, Janssen
- Alison Bond, Director Global Regulatory Policy & Intelligence, Global Regulatory Affairs, Janssen
- Anne Czwarno, Senior Manager, Vaccines Europe **TC**

Organisational and time recording:

NN.NN 17.07

Next meeting: 5 December 2016
